)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Cytosorbents (CTSO) investor relations material
Cytosorbents Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary18 Nov, 2025
Technology and product overview
Platform blood purification technology removes toxins and harmful substances from blood, with plug-and-play compatibility for hospital blood pump infrastructure.
CytoSorb, the flagship product, is EU-approved, with nearly 300,000 treatments in over 70 countries and 71% product gross margins.
DrugSorb-ATR, an investigational device, targets bleeding in patients on blood thinners during cardiac surgery and holds two FDA breakthrough device designations.
The technology is protected by 22 issued U.S. patents and has received about $50 million in U.S. government grants.
CytoSorb removes a broader range of harmful substances than dialysis, including large molecules and fat-soluble drugs.
Clinical applications and market opportunity
CytoSorb addresses severe inflammation in critical illnesses, targeting conditions like sepsis, burn injury, liver failure, and cardiac surgery complications.
Potential to treat 40%-60% of ICU patients, a much larger market than chronic kidney disease.
Sepsis accounts for roughly half of all treatments, representing a significant global market.
DrugSorb-ATR addresses a $1 billion U.S. market by enabling urgent surgery for patients on blood thinners without delay.
The device can remove multiple classes of blood thinners, including Brilinta, ELIQUIS, and XARELTO.
Regulatory and commercialization strategy
DrugSorb-ATR's initial De Novo FDA submission was denied due to efficacy data gaps, but most issues have been resolved through collaborative discussions.
FDA found no safety concerns and agreed to limit the new De Novo review to remaining open items, streamlining the process.
A new De Novo submission is planned for Q1 2026, with a regulatory decision anticipated by mid-2026.
Commercialization in the U.S. will use a direct sales model, starting with a controlled market release and a small, regionally focused sales force.
The company is eligible for NTAP and TCET reimbursement programs, supporting market adoption.
DrugSorb ATR: Confidence in new FDA submission?
DrugSorb ATR initial commercialization strategy
Germany sales growth: Impact of restructuring?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cytosorbents earnings date
Q4 202512 Mar, 2026
Next Cytosorbents earnings date
Q4 202512 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cytosorbents Corporation is a medical device company specializing in blood purification technologies. The company develops and markets the CytoSorb adsorber, a device designed to reduce harmful substances such as cytokines, toxins, and metabolic waste from the bloodstream. These technologies are used in critical care and cardiac surgery applications to manage conditions like sepsis, inflammation, and organ failure. The company is headquartered in Princeton, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage